NASDAQ:PROF

Profound Medical Competitors

$18.74
-1.32 (-6.58 %)
(As of 04/20/2021 04:30 PM ET)
Add
Compare
Today's Range
$18.66
Now: $18.74
$20.09
50-Day Range
$18.63
MA: $21.22
$23.42
52-Week Range
$11.06
Now: $18.74
$28.97
Volume47,775 shs
Average Volume82,728 shs
Market Capitalization$380.23 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45

Competitors

Profound Medical (NASDAQ:PROF) Vs. CSII, ATEC, LUNG, MDXG, ATRI, and SIBN

Should you be buying PROF stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Profound Medical, including Cardiovascular Systems (CSII), Alphatec (ATEC), Pulmonx (LUNG), MiMedx Group (MDXG), Atrion (ATRI), and SI-BONE (SIBN).

Cardiovascular Systems (NASDAQ:CSII) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Cardiovascular Systems and Profound Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cardiovascular Systems$236.54 million6.58$-27,240,000.00($0.79)-49.05
Profound Medical$4.17 million91.18$-15,220,000.00($1.37)-13.68

Profound Medical has lower revenue, but higher earnings than Cardiovascular Systems. Cardiovascular Systems is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

89.7% of Cardiovascular Systems shares are held by institutional investors. Comparatively, 35.9% of Profound Medical shares are held by institutional investors. 3.0% of Cardiovascular Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Cardiovascular Systems and Profound Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cardiovascular Systems-10.12%-11.43%-8.36%
Profound Medical-275.12%-33.69%-29.34%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Cardiovascular Systems and Profound Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cardiovascular Systems00703.00
Profound Medical00413.20

Cardiovascular Systems presently has a consensus target price of $47.5714, indicating a potential upside of 22.76%. Profound Medical has a consensus target price of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Cardiovascular Systems.

Risk and Volatility

Cardiovascular Systems has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Summary

Cardiovascular Systems beats Profound Medical on 8 of the 15 factors compared between the two stocks.

Alphatec (NASDAQ:ATEC) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, dividends and analyst recommendations.

Earnings & Valuation

This table compares Alphatec and Profound Medical's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alphatec$113.43 million13.35$-57,000,000.00($1.09)-14.61
Profound Medical$4.17 million91.18$-15,220,000.00($1.37)-13.68

Profound Medical has lower revenue, but higher earnings than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

31.8% of Alphatec shares are held by institutional investors. Comparatively, 35.9% of Profound Medical shares are held by institutional investors. 28.2% of Alphatec shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Alphatec and Profound Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Alphatec-51.95%-266.45%-40.80%
Profound Medical-275.12%-33.69%-29.34%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Alphatec and Profound Medical, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Alphatec00703.00
Profound Medical00413.20

Alphatec presently has a consensus target price of $15.4286, indicating a potential downside of 3.09%. Profound Medical has a consensus target price of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Alphatec.

Risk and Volatility

Alphatec has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Profound Medical has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500.

Summary

Profound Medical beats Alphatec on 8 of the 15 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, dividends and analyst recommendations.

Valuation & Earnings

This table compares Pulmonx and Profound Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million46.07$-20,700,000.00N/AN/A
Profound Medical$4.17 million91.18$-15,220,000.00($1.37)-13.68

Profound Medical has lower revenue, but higher earnings than Pulmonx.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Pulmonx and Profound Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Profound Medical00413.20

Pulmonx currently has a consensus price target of $58.00, indicating a potential upside of 37.83%. Profound Medical has a consensus price target of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts plainly believe Profound Medical is more favorable than Pulmonx.

Insider & Institutional Ownership

35.9% of Profound Medical shares are owned by institutional investors. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Pulmonx and Profound Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Profound Medical-275.12%-33.69%-29.34%

Summary

Profound Medical beats Pulmonx on 6 of the 11 factors compared between the two stocks.

Profound Medical (NASDAQ:PROF) and MiMedx Group (NASDAQ:MDXG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Profound Medical has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, MiMedx Group has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Profound Medical and MiMedx Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Profound Medical00413.20
MiMedx Group00103.00

Profound Medical presently has a consensus target price of $31.4167, indicating a potential upside of 67.64%. MiMedx Group has a consensus target price of $20.00, indicating a potential upside of 84.67%. Given MiMedx Group's higher possible upside, analysts clearly believe MiMedx Group is more favorable than Profound Medical.

Earnings & Valuation

This table compares Profound Medical and MiMedx Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profound Medical$4.17 million91.18$-15,220,000.00($1.37)-13.68
MiMedx Group$299.26 million4.03$-25,580,000.00N/AN/A

Profound Medical has higher earnings, but lower revenue than MiMedx Group.

Institutional & Insider Ownership

35.9% of Profound Medical shares are owned by institutional investors. Comparatively, 4.0% of MiMedx Group shares are owned by institutional investors. 19.8% of MiMedx Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and MiMedx Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Profound Medical-275.12%-33.69%-29.34%
MiMedx Group-37.28%-404.08%-58.81%

Summary

Profound Medical beats MiMedx Group on 8 of the 14 factors compared between the two stocks.

Profound Medical (NASDAQ:PROF) and Atrion (NASDAQ:ATRI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Profound Medical has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, Atrion has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Profound Medical and Atrion, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Profound Medical00413.20
Atrion0000N/A

Profound Medical presently has a consensus target price of $31.4167, indicating a potential upside of 67.64%. Given Profound Medical's higher possible upside, analysts clearly believe Profound Medical is more favorable than Atrion.

Earnings & Valuation

This table compares Profound Medical and Atrion's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profound Medical$4.17 million91.18$-15,220,000.00($1.37)-13.68
Atrion$155.07 million7.68$36.76 millionN/AN/A

Atrion has higher revenue and earnings than Profound Medical.

Institutional & Insider Ownership

35.9% of Profound Medical shares are owned by institutional investors. Comparatively, 63.2% of Atrion shares are owned by institutional investors. 22.4% of Atrion shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and Atrion's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Profound Medical-275.12%-33.69%-29.34%
Atrion21.90%13.90%12.55%

Summary

Atrion beats Profound Medical on 8 of the 13 factors compared between the two stocks.

Profound Medical (NASDAQ:PROF) and SI-BONE (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, risk, profitability, dividends and earnings.

Risk & Volatility

Profound Medical has a beta of 1.45, suggesting that its share price is 45% more volatile than the S&P 500. Comparatively, SI-BONE has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Profound Medical and SI-BONE, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Profound Medical00413.20
SI-BONE00503.00

Profound Medical presently has a consensus target price of $31.4167, indicating a potential upside of 67.64%. SI-BONE has a consensus target price of $33.20, indicating a potential downside of 0.78%. Given Profound Medical's stronger consensus rating and higher possible upside, analysts clearly believe Profound Medical is more favorable than SI-BONE.

Earnings & Valuation

This table compares Profound Medical and SI-BONE's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Profound Medical$4.17 million91.18$-15,220,000.00($1.37)-13.68
SI-BONE$67.30 million16.27$-38,400,000.00($1.55)-21.59

Profound Medical has higher earnings, but lower revenue than SI-BONE. SI-BONE is trading at a lower price-to-earnings ratio than Profound Medical, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

35.9% of Profound Medical shares are owned by institutional investors. Comparatively, 65.3% of SI-BONE shares are owned by institutional investors. 15.5% of SI-BONE shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Profound Medical and SI-BONE's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Profound Medical-275.12%-33.69%-29.34%
SI-BONE-61.67%-45.03%-29.29%

Summary

Profound Medical beats SI-BONE on 9 of the 15 factors compared between the two stocks.


Profound Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.5$38.75-0.2%$1.56 billion$236.54 million-58.71News Coverage
Alphatec logo
ATEC
Alphatec
0.8$15.92-1.9%$1.51 billion$113.43 million-14.47
Pulmonx logo
LUNG
Pulmonx
1.4$42.08-3.9%$1.50 billion$32.60 million0.00
MiMedx Group logo
MDXG
MiMedx Group
1.7$10.83-4.7%$1.26 billion$299.26 million-11.52News Coverage
Atrion logo
ATRI
Atrion
1.1$651.58-0.2%$1.19 billion$155.07 million36.71
SI-BONE logo
SIBN
SI-BONE
1.2$33.46-3.7%$1.10 billion$67.30 million-20.91Analyst Report
News Coverage
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$53.91-0.1%$1.06 billion$189.49 million-119.80
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$50.03-0.9%$1.03 billion$117.23 million53.80News Coverage
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$52.07-0.3%$1.02 billion$72.55 million-36.16Analyst Report
News Coverage
Cerus logo
CERS
Cerus
1.7$5.84-1.4%$995.86 million$74.65 million-14.97News Coverage
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.54-1.7%$897.75 million$264.16 million-5.27Decrease in Short Interest
CryoLife logo
CRY
CryoLife
2.0$22.54-0.2%$881.77 million$276.22 million-59.31News Coverage
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.89-0.3%$854.04 million$459.95 million36.58
Surmodics logo
SRDX
Surmodics
1.3$57.51-0.3%$789.04 million$94.86 million718.88
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$9.42-0.8%$683.49 million$154.60 million-40.96
Intersect ENT logo
XENT
Intersect ENT
1.7$19.50-0.9%$649.76 million$109.14 million-10.21Analyst Upgrade
News Coverage
Antares Pharma logo
ATRS
Antares Pharma
1.8$3.84-1.6%$645.74 million$123.86 million64.01
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$40.60-1.6%$572.63 million$114.51 million-86.38
SeaSpine logo
SPNE
SeaSpine
1.5$19.82-0.7%$557.70 million$159.08 million-11.87
Vapotherm logo
VAPO
Vapotherm
1.5$21.30-0.9%$549.69 million$48.10 million-10.14
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$19.93-2.3%$526.11 millionN/A-8.78
Accuray logo
ARAY
Accuray
2.3$4.93-4.7%$457.99 million$382.93 million35.21Upcoming Earnings
News Coverage
iCAD logo
ICAD
iCAD
1.7$16.99-3.6%$438.56 million$31.34 million-17.88
AVITA Medical logo
RCEL
AVITA Medical
1.5$19.87-1.3%$435.18 million$14.26 million-9.60
Cytosorbents logo
CTSO
Cytosorbents
1.7$8.75-2.3%$378.56 million$24.95 million-26.52News Coverage
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.87-0.1%$375.32 million$198.38 million24.94
PAVmed logo
PAVM
PAVmed
1.4$4.26-5.6%$371.07 millionN/A-5.61
Acutus Medical logo
AFIB
Acutus Medical
1.3$12.91-0.2%$362.71 million$2.84 million0.00News Coverage
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$17.48-1.4%$361.36 million$11.22 million-39.73
Soliton logo
SOLY
Soliton
1.2$14.67-7.4%$334.11 millionN/A-19.56Analyst Downgrade
Analyst Revision
News Coverage
Apyx Medical logo
APYX
Apyx Medical
1.0$9.88-2.4%$330.83 million$28.15 million-21.02
IRadimed logo
IRMD
IRadimed
1.5$25.85-1.4%$318.24 million$38.52 million80.78
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$87.04-0.1%$317.82 million$46.90 million27.46Upcoming Earnings
News Coverage
Neuronetics logo
STIM
Neuronetics
1.5$10.76-3.2%$285.65 million$62.66 million-6.40News Coverage
DarioHealth logo
DRIO
DarioHealth
1.3$16.52-4.3%$254.33 million$7.56 million-2.07
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$8.19-7.4%$234.78 million$220,000.0010.11Gap Up
TELA Bio logo
TELA
TELA Bio
2.1$13.56-0.1%$196.10 million$15.45 million-4.66
Titan Medical logo
TMDI
Titan Medical
1.2$1.49-7.4%$175.24 millionN/A149.00Gap Up
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.18-0.0%$175.22 million$8.34 million-1.71
PolyPid logo
PYPD
PolyPid
1.4$9.59-1.7%$163.47 millionN/A0.00News Coverage
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.72-8.4%$161.10 million$50.71 million-4.61Decrease in Short Interest
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.02-5.6%$134.32 million$23.16 million-302.00
Brainsway logo
BWAY
Brainsway
1.4$8.30-7.5%$131.66 million$23.10 million-25.94Analyst Upgrade
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$10.15-8.0%$131.57 millionN/A0.00Gap Up
Liquidia logo
LQDA
Liquidia
1.5$2.83-4.2%$122.64 million$8.07 million-1.33Analyst Downgrade
Nemaura Medical logo
NMRD
Nemaura Medical
0.2$4.91-8.1%$121.76 millionN/A-24.55Increase in Short Interest
Beyond Air logo
XAIR
Beyond Air
1.7$5.21-1.9%$108.79 million$1.39 million-3.32
Avinger logo
AVGR
Avinger
1.4$0.97-13.4%$104.83 million$9.13 million-0.74Analyst Downgrade
Decrease in Short Interest
Venus Concept logo
VERO
Venus Concept
1.9$1.77-6.2%$101.47 million$110.41 million-0.53
Pro-Dex logo
PDEX
Pro-Dex
0.7$25.98-0.9%$100.31 million$34.83 million26.97Increase in Short Interest
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.